,for, Item ID-
  • #1233685
  • Boehringer Ingelheim #00597018230

GLYXAMBI® Empagliflozin / Linagliptin 10 mg - 5 mg Tablet 30 Tablets

GLYXAMBI, TAB 10MG/5MG (30/BT)

No Image

Features

  • GLYXAMBI is a combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease
  • More …
Strength
10 mg - 5 mg 25 mg - 5 mg
  Log In to Order
or

Product Specifications


Features
  • GLYXAMBI is a combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease

Professionals Also Viewed